Geron CFO Olivia Kyusuk Bloom Unloads 3,379 Shares (GERN)
Geron (NASDAQ:GERN) CFO Olivia Kyusuk Bloom unloaded 3,379 shares of Geron stock in a transaction that occurred on Thursday, May 29th. The shares were sold at an average price of $2.10, for a total value of $7,095.90. Following the sale, the chief financial officer now directly owns 81,968 shares of the company’s stock, valued at approximately $172,133. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
Shares of Geron (NASDAQ:GERN) traded down 1.89% during mid-day trading on Friday, hitting $2.08. 2,891,681 shares of the company’s stock traded hands. Geron has a one year low of $1.06 and a one year high of $7.79. The stock has a 50-day moving average of $1.94 and a 200-day moving average of $3.76. The company’s market cap is $326.4 million.
Geron (NASDAQ:GERN) last issued its quarterly earnings data on Thursday, May 1st. The company reported ($0.06) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.06). The company had revenue of $0.47 million for the quarter, compared to the consensus estimate of $0.35 million. During the same quarter in the previous year, the company posted ($0.09) earnings per share. The company’s revenue for the quarter was down 38.0% on a year-over-year basis. On average, analysts predict that Geron will post $-0.25 earnings per share for the current fiscal year.
A number of research firms have recently commented on GERN. Analysts at Zacks reiterated a “neutral” rating on shares of Geron in a research note on Tuesday. They now have a $2.25 price target on the stock. Finally, analysts at Wells Fargo & Co. reiterated a “positive” rating on shares of Geron in a research note on Thursday, March 13th. Five investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus target price of $2.13.
Geron Corporation (NASDAQ:GERN) is a clinical-stage biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.